Ondine Biomedical Revises Results Timeline for US Phase 3 Study of Nasal Photodisinfection Technology

Ondine Biomedical (OBI.L) said Monday it revised the timeline for results of its Lantern phase 3 study in the US evaluating its antibiotic nasal photodisinfection technology. The results are now expected within six weeks following recent guidance from the life sciences company's independent data management and statistical advisers. The technology, branded as Steriwave outside the US, is intended to reduce surgical site infections. The study's primary endpoint and success criteria are unchanged, Ondine added.